What the name refers to
Afamelanotide is an alpha-MSH analogue authorised in a controlled implant for erythropoietic protoporphyria; online Melanotan I products are not equivalent.
Evidence and regulatory context
Medical use or authorisation exists historically or in limited jurisdictions. Current availability, indications and legal classification must be checked against the regulator for the reader’s location.
Reading product records
Authorisation often belongs to a particular branded formulation, device, indication and professional setting—not to a broad ingredient name. Records should emphasise manufacturer, market-specific approval, batch, cold-chain or storage requirements and supply-chain provenance.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.